Ensidipine effects and side effects

Enasidenib (Enasidenib), as an oral targeted inhibitor, is mainly used to treat specific types of acute myeloid leukemia (AML). Its mechanism of action involves the inhibition of IDH2 (isocitrate dehydrogenase 2) mutant enzyme, thereby affecting the production of abnormal metabolites, restoring normal cell function, and ultimately inhibiting the development of AML. However, as with any drug treatment, ensidipine may cause some side effects. Their effects and side effects are discussed in detail below.

Mechanism of action:

1. Inhibition of IDH2mutant enzyme: Ensidipine is a specific IDH2mutant enzyme inhibitor. By binding to the IDH2mutated enzyme and blocking its activity, ensidipine can reduce the production of 2-hydroxyglutarate (2-HG), thereby restoring normal cell metabolism and function.

2.Inhibition of leukemia cell proliferation: By reducing the level of 2-HG, ensidipine can reduce the promotion effect on AML cells and inhibit the proliferation and survival of leukemia cells.

3.Promote cell differentiation: Treatment with ensidipine may help promote the differentiation of leukemia cells into mature hematopoietic cells, thereby further inhibiting the development ofAML.

Side effects:

1.Digestive system side effects: including nausea, vomiting, diarrhea, indigestion, etc. These side effects usually appear within a few weeks of starting treatment and gradually decrease as treatment continues.

2.Liver function abnormalities: Some patients may develop liver function abnormalities, such as elevated liver enzymes and bilirubin levels. This may require regular monitoring and adjustments to treatment regimen.

3.Developmental myeloid abnormalities: Developmental myeloid abnormalities in the bone marrow may be observed during ensidipine treatment. This can lead to symptoms such as anemia, thrombocytopenia, and leukopenia.

5.Adverse reactions and other symptoms related to treatment: including fatigue, headache, joint pain, rash, etc. These symptoms are usually mild and temporary, but may last longer in some patients.

6.Other serious adverse reactions: includingQT interval prolongation, secondary leukemia and bleeding. Although these reactions are relatively rare, they may have a serious impact on the patient's health.

Ensidipine is a targeted inhibitor for the treatment of AML. Its mechanism of action involves the inhibition of IDH2 mutant enzyme, thereby restoring normal cell function and inhibiting the development of AML. However, as with any drug treatment, ensidipine may cause some side effects, including digestive side effects, liver function abnormalities, developmental myeloid abnormalities, etc. Therefore, when using ensidipine for treatment, patients should pay close attention to any possible adverse reactions and report them to their doctors in time so that the treatment plan can be adjusted in a timely manner.